作者: Yayoi Yoshimura , Akihiko Shiino , Kazue Muraki , Tadateru Fukami , Shigeki Yamada
DOI: 10.1371/JOURNAL.PONE.0128288
关键词:
摘要: Glioblastoma multiforme (GBM) is associated with high mortality due to infiltrative growth and recurrence. Median survival of the patients less than 15 months, increasing requirements for new therapies. We found that both arsenic trioxide 10058F4, an inhibitor Myc, induced differentiation cancer stem-like cells (CSC) GBM drastically enhanced anti-proliferative effect 10058F4 but not apoptotic effects. EGFR-driven genetically engineered mouse model showed this cooperative higher in EGFRvIII-expressing INK4a/Arf-/- neural stem (NSCs) control wild type NSCs. In addition, treatment CSC xenografts resulted significant decrease tumor increased concomitant proneural mesenchymal CSCs vivo. Our study was first evaluate interaction assess opportunities combination as a promising approach future therapy GBM.